|
Bristol-Myers Squibb News is an EIN News Service for health professionals. Constantly updated news and information about health.
Latest Bristol-Myers Squibb News
- In recession, some firms made wise cuts; others didn't 8 Nov 2009 04:37 GMT
... are likely to pay off are Procter & Gamble Co., General Electric Co. and Bristol Myers Squibb. Government intervention has done some good, Wright said, but it has produced no miracles. ...
- Comparative Effectiveness With the Gloves Off 8 Nov 2009 05:39 GMT
... Health Solutions announced the initiation of a new study making a head-to-head comparison of Bristol-Myers Squibb’s heart drug Plavix (clopidrogel)—a years-old blockbuster drug—and newly introduced Effient (prasugel) from Eli ...
- News and FDA Updates for S3 Investment (OTC:SIVC), Bristol-Myers (NYSE:BMY) 7 Nov 2009 08:30 GMT
... and FDA Updates for S3 Investment (OTC:SIVC), Bristol-Myers (NYSE:BMY) Pasadena, CA - 11/06/09 - BioMedReports.Headlines ... in the China market. On 11/05/09, Bristol-Myers Squibb Company (NYSE:BMY) announced the U.S. Food and ...
- FDA Approves Labeling Update for Reyataz (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients 7 Nov 2009 02:32 GMT
... Data for Previously Untreated HIV-1 Infected Adult Patients PRINCETON, N.J.--(BUSINESS WIRE)--Nov 5, 2009 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved a ...
- Drug Brings Wake-Up Call in Depression and OSA 7 Nov 2009 00:14 GMT
... Transcept Pharmaceuticals, Actelion, Arena, Lilly, Neurim, Neurocrine, Neurogen, Organon, Somaxon, Axiom Pharmaceuticals, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Jazz Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, King Pharmaceuticals, Novartis Pharmaceuticals Corporation, ...
- Cravaths Act on Hyatt Hotel Corp's $1.09 Billion Capital Raising - American Legal Business 7 Nov 2009 06:14 GMT
... Halpern -Skoglund (executive compensation and benefits). Cravath also represented Mead Johnson, a division of Bristol Myers-Squibb, in the first U.S. initial public offering in 2009. ...
- Healthcare proves hard test for Aetna 7 Nov 2009 14:52 GMT
... cyclical stocks and, expecting a slower growth environment, moved into consumer staples such as Bristol-Myers Squibb. "We like the team, we like the strategy, we like the results," said Greg ...
- KIT digital and IMG Enter Into Agreement 7 Nov 2009 19:13 GMT
... more than 600 enterprise customers across 30+ countries, including The Associated Press, Best Buy, Bristol-Myers Squibb, Disney-ABC, General Motors, Google, IMG Worldwide, Intel, McDonald's, News Corp, Telefonica, the U.S. Department ...
- New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel 7 Nov 2009 19:18 GMT
... and S1P. Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen/Pfizer, Arana, Array, AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Centocor/Schering-Plough, Cytopia, Genentech/Roche, Genentech/Roche/Chugai, GlaxoSmithKline/Genmab, GSK/Human Genome Sciences, Incyte, Lexicon, Lilly, Merck, Merck ...
- Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development 2 Nov 2009 13:31 GMT
... Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development ALBANY, N.Y. - (BUSINESS WIRE) - AMRI (NASDAQ: AMRI) ...
- Taisho Pharmaceutical acquires 97.97% stake in PT Bristol-Myers Squibb Indonesia Deal In Brief 2 Nov 2009 18:51 GMT
... Taisho Pharmaceutical acquires 97.97% stake in PT Bristol-Myers Squibb Indonesia Deal In Brief Nov 02, 2009 (Datamonitor Financial Deals Tracker via COMTEX News ...
- Taisho Pharmaceutical acquires Tempra(R), Counterpain(R), Theragran-M(R), Engran(R), Ceetrus(R), and Keri(R) brands from Bristol-Myers Squibb Deal In Brief 2 Nov 2009 18:51 GMT
... Taisho Pharmaceutical acquires Tempra(R), Counterpain(R), Theragran-M(R), Engran(R), Ceetrus(R), and Keri(R) brands from Bristol-Myers Squibb Deal In Brief Nov 02, 2009 (Datamonitor Financial Deals Tracker via COMTEX News Network) ...
- AMRI receives $750,000 milestone payment from Bristol-Myers Squibb 3 Nov 2009 11:16 GMT
... today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE: BMY) will proceed into preclinical development. AMRI will receive a $750,000 payment ...
- Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C 2 Nov 2009 10:11 GMT
... moving to dose-ranging Phase II studies in treatment-naïve HCV patients PRINCETON, N.J. & SEATTLE(BUSINESS WIRE)Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a ...
- Bristol-Myers Squibb, ZymoGenetics Release Final Phase 1b Results For PEG-Interferon Lambda 2 Nov 2009 08:13 GMT
... Bristol-Myers Squibb, ZymoGenetics Release Final Phase 1b Results For PEG-Interferon Lambda PEG-Interferon lambda demonstrated antiviral activity ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
bbc.co.uk:
healthday.com:
reuters.com: